The medical device firm reports $94.5 million Q2 revenue, up 19% year-over-year, as it targets profitability by late 2026.
Procept BioRobotics projected 54,000 to 56,000 U.S. procedures for 2026 while aiming for positive adjusted EBITDA in Q4 2026. The guidance follows a Q2 2026 performance where revenue reached $94.5 million, a 19% year-over-year increase.
The company completed over 13,100 U.S. procedures in Q2, growing 21% year-over-year. Management noted the growth was strong but softer than expected, without providing further details on the shortfall.
No immediate market reaction was disclosed in the earnings call insights.